Cantargia

Sweden
Lund, Skane Lan, Sweden
+46 4 62 75 62 60 ★

Company profile

Cantargia company profile

The company is based on the original discovery that leukemic stem cells in patients with chronic myeloid leukemia (CML) express a cell-surface receptor, whereas corresponding normal hematopoietic stem cells do not express this receptor. Stem cells from patients with acute myeloid leukemia (AML) and acute lymphocytic leukemia (ALL) has also been shown to have and upregulation of the receptor. Cantargia uses this receptor, the Interleukin-1 receptor accessory protein (IL1RAP), as the target for development of a novel antibody-based therapy for leukemia

Business identity

Contact email
[email protected]
Phone number
+46 4 62 75 62 60
Operating status
Active
Company type
For Profit
Employee range
00011-00050 employees
Revenue range
$0+
Founded
2010-01-01

Headquarters

Headquarters
Lund, Skane Lan, Sweden
Postal code
223 81
Country code
SE
Continent
Europe

Capital profile

Funding and company signals

Funding stage
Ipo
Funding rounds
3
Total equity funding
$25.8M
Last funding
Post Ipo Debt / $2.6M / 2025-06-17
Last equity funding
Post Ipo Equity / $24.7M
Investors
3
Lead investors
1
Founders
2
Articles
156
Exited on
2016-01-01

Founders and investors

Founders

Marcus JarasThoas Fioretos

Lead investors

Fenja Capital

Investors

Fenja CapitalLubio ScienceSunstone Life Science Ventures

People at this company

Preview only. Contact details are available after you sign in.

Log in to view people and contact details at this company

Contact information and company affiliations may no longer be accurate. Verify details before reaching out.

Shipment data

Explore detailed shipment data

Sign in to view shipment history, products, suppliers, and trade lanes for this company.

Log in to view shipment data

Shipment records and coverage can change as the dataset is updated.